SCHEMBL23218688

SCHEMBL23218688

BrCc1coc2c1cc(Br)c1occc12

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
PTPN1 P18031 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592513 1.00 HTR2A (0.33) HTR2AHTR2CHTR2BPTPN1
SCHEMBL23219223 0.88 HTR2A (0.33) HTR2AHTR2CHTR2B
SCHEMBL29591185 0.88 HTR2A (0.33) HTR2AHTR2CHTR2B
SCHEMBL23218517 0.76 KCNA3 (0.35) HTR2AHTR2CHTR2BPTPN1
SCHEMBL29591905 0.76 KCNA3 (0.35) HTR2AHTR2CHTR2BPTPN1
SCHEMBL23218372 0.76 SIRT2 (0.35) PTPN1
SCHEMBL23219171 0.75 HTR2A (0.33) HTR2AHTR2CHTR2B
SCHEMBL29591406 0.74
SCHEMBL23219152 0.74
SCHEMBL19683573 0.73 HTR2A (0.38) HTR2AHTR2CHTR2BPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed